Literature DB >> 15109274

Levamisole in dermatology : a review.

Noah Scheinfeld1, Joshua D Rosenberg, Jeffrey M Weinberg.   

Abstract

Levamisole, an anthelmintic agent with a wide range of immunomodulatory actions, has been used successfully as monotherapy and an adjunct to treatment in a variety of diseases. Since 1990, combination therapy of levamisole and fluorouracil has played an important role in the treatment of resected Dukes stage C adenocarcinoma of the colon. Because of its immunomodulating effects levamisole has been used in a wide range of diseases with and without success. In dermatologic disease levamisole has been successfully used in the treatment of parasitic, viral and bacterial infections including leprosy, collagen vascular diseases, inflammatory skin diseases and children with impaired immune a variety of reasons. It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth. Adverse affects of levamisole are mild and infrequent and include rash, nausea, abdominal cramps, taste alteration, alopecia, arthralgia, and a flu-like syndrome. It can rarely cause agranulocytosis. More studies need to be undertaken to study the full potential of levamisole in dermatologic diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15109274     DOI: 10.2165/00128071-200405020-00004

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  9 in total

1.  Synthesis, Molecular Docking and Preliminary Antileukemic Activity of 4-Methoxybenzyl Derivatives Bearing Imidazo[2,1-b][1,3,4]thiadiazole.

Authors:  B Choodamani; Karla G Cano Hernandez; Sujeet Kumar; Ann Maria Tony; Austre Y Schiaffino Bustamante; Renato J Aguilera; Dominique Schols; C Gopi Mohan; Subhas S Karki
Journal:  Chem Biodivers       Date:  2021-01-07       Impact factor: 2.408

2.  Regression of major recurrent aphthous ulcerations using a combination of intralesional corticosteroids and levamisole: a case report.

Authors:  Bruna Lavinas Sayed Picciani; Geraldo Oliveira Silva-Junior; Davi Silva Barbirato; Ruth Tramontani Ramos; Marilia Heffer Cantisano
Journal:  Clinics (Sao Paulo)       Date:  2010-06       Impact factor: 2.365

Review 3.  DARK Classics in Chemical Neuroscience: Aminorex Analogues.

Authors:  Julian Maier; Felix P Mayer; Simon D Brandt; Harald H Sitte
Journal:  ACS Chem Neurosci       Date:  2018-10-05       Impact factor: 5.780

Review 4.  Immunomodulators in warts: Unexplored or ineffective?

Authors:  Surabhi Sinha; Vineet Relhan; Vijay K Garg
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

Review 5.  Evolving role of immunotherapy in the treatment of refractory warts.

Authors:  Devinder M Thappa; Minu J Chiramel
Journal:  Indian Dermatol Online J       Date:  2016 Sep-Oct

6.  Effect of a Single and Triple Dose of Levamisole on Hematological Parameters in Controlled Inflammation Model.

Authors:  Piotr Kuropka; Anna Leśków; Katarzyna Małolepsza-Jarmołowska; Maciej Dobrzyński; Małgorzata Tarnowska; Jacek Majda; Maciej Janeczek; Katarzyna Żybura-Wszoła; Andrzej Gamian
Journal:  Animals (Basel)       Date:  2022-08-17       Impact factor: 3.231

7.  Clinical features and magnetic resonance image analysis of 15 cases of demyelinating leukoencephalopathy induced by levamisole.

Authors:  Ruifang Yan; Qingwu Wu; Jipeng Ren; Hongkai Cui; Kaihua Zhai; Zhansheng Zhai; Qinghong Duan
Journal:  Exp Ther Med       Date:  2013-04-24       Impact factor: 2.447

Review 8.  Anti-helminthic drugs in recurrent apthous stomatitis: A short review.

Authors:  Shilpa Sharma; Fareedi Mukram Ali; Kedar Saraf; Anupama Mudhol
Journal:  J Pharm Bioallied Sci       Date:  2014-04

9.  Uncommon Neurological Complications of Levamisole.

Authors:  Prasanna V Eswaradass; Balamurugan Namasivayam
Journal:  Ann Indian Acad Neurol       Date:  2020-12-08       Impact factor: 1.383

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.